NexImmune stock shows a 50.0 percent one-year loss

Published on 09/25/2026 at 16:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NexImmune stock carries trailing net income of negative USD 20.62 million as shown on September 23, 2026. Diluted EPS is negative USD 18.5100 and cash is USD 2.42 million.

NEXI, US65343B1044, Illustration mit AI erstellt.

NexImmune stock (ISIN US65343B1044) shows a 50.0 percent one-year loss as of March 13, 2025, according to Folivue. A September 23, 2026 profile from Yahoo Finance identifies the issuer as a clinical-stage biotechnology company developing T cell immunotherapies.

Returns show a sharp split

Folivue lists NEXI's one-year total return at negative 50.0 percent and its year-to-date total return at positive 0.0 percent. The comparison places the longer-term performance clearly below the unchanged year-to-date result, with dividends reinvested in both measures.

The same profile records an all-time high of USD 647.75 in February 2021. That historical peak illustrates the distance between the company's early public-market valuation and the later biotechnology profile described by the company.

Trailing figures remain negative

Yahoo Finance lists trailing net income attributable to common shareholders at negative USD 20.62 million, diluted trailing EPS at negative USD 18.5100, and total cash at USD 2.42 million on its most recent quarterly balance-sheet field. Revenue is shown as an empty field, so the operating picture is defined by the loss, cash balance and clinical pipeline rather than a sales figure.

The company profile names NEXI-001 for acute myeloid leukemia, NEXI-002 for multiple myeloma, NEXI-003 for HPV-related cancers and NEXI-004 for EBV-related diseases. The first three candidates are described as being in Phase I/II trials, while NEXI-004 is in preclinical development.

Nasdaq listing and pipeline

The investor-relations page identifies the security as NASDAQ: NEXI and describes the company as developing its Artificial Immune Modulation platform. It also lists a USD 3.67 million registered direct offering that closed on February 6, 2024, according to NexImmune.

One-year return stays negative

As of March 13, 2025, NEXI's one-year total return stood at negative 50.0 percent versus positive 0.0 percent year to date. The dated return comparison, negative trailing earnings and USD 2.42 million cash balance define the measurable profile of NexImmune stock.